second to call. Thank Helius earnings quarter Michelle. conference you, everyone, XXXX Welcome, Medical's
year systems Increased sales the I'm happy which prior the saw revenue PoNS of compared neurologists the XX, XXXX. patients. compared first up PoNS sales to under PTAP XXX% that program, the significant part of quarter U.S. to during offered a revenues the and certified trained to and we the quarter up drove quarter ongoing XXXX, in recommending of of second pricing therapists, with higher did XXX% increase report June through on in terminated their to as the PoNS favorable XXXX, addition
at Therapy treatment people gait impairment. ago suffering Americans launched eliminating the barriers from from balance We year reimbursement scheduled many initially PoNS get balance important and has program's PTAP ability suffering the due neuro gait MS, one the third-party is XX. possible extended lessening our as initiated efforts December groundbreaking hands qualified to a June technology been we qualified to the XXXX, impairment on expire and purchase a but for by use. goal price, into and to due this Since to give beginning, XX, patients to the CMS. of to to we PTAP it to payers pursue burden PoNS to by significantly popularity, cost reduced while was
registry to registry therapeutic add to information a data on PoNS reimbursement. key health outcomes. patient to the value element establish clinical of our PTAP major brought PoNS patients to a also enabled we than to great us barrier By was Therapy number participants, success. otherwise use and and key collect This MS important pursuing PTAP for to the of economic and great patient meaningfully a have. is relief would we subsidizing reduced
cash be as pursue basis forward, aggressively continually of navigate pathway. the systems to helping while also PoNS on Going reimbursement a we sales will coverage patients
TCET, coverage Emerging medical and Technologies reimbursement proposed Program to payer Coverage before, believe innovative broad new is As needed pathway and Transitional about our a CMS' revenue we is full which achieve remain accelerated very I've potential, devices. or we third-party mentioned optimistic for of
coverage and development. opportunity for reviews provided the would the devices its June, The announced manufacturers TCET expedite allowing with approach Medicare increased proposed TCET pathway engagement breakthrough of to and coverage by CMS clarification certain evidence its premarket proposed In CMS. greater pathway on
coverage greater Through to premarket months the clinical breakthrough gather Helius gaps. and their designations coverage evaluation stroke about aims breakthrough Under would news necessary FDA MS address both is guidelines, the new in great after products This companies PoNS of any technologies in efficacy qualifying United temporary designations prove and authorization, identification options. data evidence the time has have gaps, and to of States. to uncertainty for allowing of evidence within important reduce six market TCET as
the by it's from or addition, an and passed. In team, component achieving wish Supplies, awarded to this recently Organizations must approved authorized accreditation is services. which and all Prosthetics, by compliance and Medicare accreditation if Orthotics products and that accredit key agency, under to in a DMEPOS coverage CMS and certification PoNS was have when is Equipment, bill Durable Medical DMEPOS TCET
updated we of of we bringing As we'll Experience known as On Therapeutic Program, a from suffering is way PoNS you path another patients achieving believe now, coverage on and developments. and we're further technology to number a PoNSTEP impairment. greater are keep balance toward in our mid-XXXX, our otherwise on gait
subjects' MS open-label setting. with As was with enrollment adherence patients a company-sponsored XX is XX real-world of PoNSTEP observational to in to the in PoNS a that evaluate targeted a patients trial impact designed to Therapy reminder, a of
Center in Christopher in Earlier Dr. we a renown PoNSTEP. Medical is Montefiore is York who first Nyack, -- and of of of Langston, to clinical management New was and researcher current week, leading the is who this topics trial advanced MS prescribers. the the the announced one addition leading PoNS
to program. Borelli the Multiple team to his We be expect Dr. Langston Sclerosis Center Madlyn and contributors great at
will than and XXXX continue goal interested Enrollment as patients originally five per enrolling fully six of the This adding quarter are during the site. is in per PoNSTEP, excellence participating the more throughout five with now site in higher of to PoNSTEP several have fourth sites we enrolled patients our in centers XX and XXXX. patients. of began We envisioned of
balance trial our the Carolina and This patients. evaluates We in of study Therapy XX stroke survivors. to dynamic expansion from PoNS recently of announced chronic delivered neuromodulation non-invasive the of Medical cranial-nerve XX on stroke effects investigator-initiated South University gait using
where PoNS Canada, meaningful and for significant our This we've seen in a in to in data for the falling. study breakthrough stroke authorized stroke, steps reduced significant forward gait leverage and In and are the approval efforts already real-world risk expanded States. improvement United of pursue designation is
in we data States. previously a real-world to similar reminder, United for from the clinical in As were receive use results able to MS authorization studies
now Canadian Canadian first revenues Turning six half months second the slipped some in The orders of anticipated half into XXXX XXXX, resulting XXXX. activity during of lower-than-expected of the originally timing have our and first in the activities. to of
Having the to market much stronger said which is and will typically year third believe could experiences result Canada strong finish this term. that, in difference authorized we for weakness than TBI. PoNS Indications: because be in a the timing near three the The larger U.S. MS, in and seasonal a market stroke quarter,
discuss let Now to results me turn the quarter detail. our over second to call in Jeff financial
